HLN
EquityHaleon plc
Health Care · Drug Manufacturers - Specialty & Generic
$11.07
+11.07 (+0.00%)
Open
N/A
Day Range
$10.94 - $11.09
52W Range
$8.71 - $11.42
Volume
5M
Price History
Key Statistics
Market Cap
N/A
P/E Ratio
N/A
EPS
N/A
Dividend Yield
N/A
P/B Ratio
N/A
Payout Ratio
N/A
ROE
N/A
Debt/Equity
N/A
Latest News
Haleon PLC Sponsored ADR (HLN) Moves to Buy: Rationale Behind the Upgrade
Haleon's weaker sales make mid-term targets 'not look credible'
Haleon (HLN) Falls 7.7% on Revenue Miss
Haleon PLC (HLN) Q4 2025 Earnings Call Highlights: Strategic Changes and Market Challenges
Haleon shares fall 3.4% as revenue growth falls short of the company's own medium-term target
Fair Value Estimate
DDM Value
$3.70
Growth: 5.0% | Req. return: 10%
Peers in Health Care
| Symbol | Name | Price | Mkt Cap | Div Yield | Change |
|---|---|---|---|---|---|
| ABCL | AbCellera Biologics Inc. | $3.61 | N/A | - | +0.00% |
| ABUS | Arbutus Biopharma Corporation | $4.66 | N/A | - | +0.00% |
| 001540.KQ | AHN-GOOK PHA | $8,070.00 | N/A | 5.45% | +0.00% |
| AKBA | Akebia Therapeutics, Inc. | $1.31 | N/A | - | +0.00% |
| AHCO | AdaptHealth Corp. | $9.15 | N/A | - | +0.00% |
| ABBV | AbbVie Inc. | $232.08 | N/A | 2.87% | +0.00% |
| ACAD | ACADIA Pharmaceuticals Inc. | $24.56 | N/A | - | +0.00% |
| CRSP | CRISPR Therapeutics AG | $60.14 | N/A | - | +0.00% |
About Haleon plc
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Aquafresh, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
www.haleon.com →Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Borderline
Based on 4 fundamental factors
Analysis Tools
Share
Dividend History
Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Borderline
Based on 4 fundamental factors
Dividend Growth
1Y CAGR
+12.1%
3Y CAGR
N/A
5Y CAGR
N/A
10Y CAGR
N/A
5-Year Dividend Projection
| Year | Conservative | Base | Optimistic |
|---|
Based on historical CAGR. Not a guarantee of future dividends.
View Full Projection →Loading financial data...
Revenue & Earnings
No financial statement data available for HLN.